ClinicalTrials.gg
CompletedNCT00740779Updated Feb 24, 2012Results posted

Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

A Phase 2 interventional study of Silodosin 8 mg and Placebo in Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome, sponsored by Watson Pharmaceuticals. Completed at 22 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-24.

Sponsored by Watson Pharmaceuticals (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Prostatitis with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Prostatitis · United States.

Enrollment
7th of 19
153 · median 62
Started
2008
with 2 others
Phase 2
6 of 24
none open now
Registered
10th of 24
by date

Among the 24 studies in Prostatitis with a site in United States, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2008, is one of 6 in phase 2, and was the 10th registered.

Prostatitis

89 studies on the registry are indexed under Prostatitis; 12 are open to participants now.

Browse Prostatitis studies →

Open to participants now

2 of the 24 studies in Prostatitis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Prostatitis studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Prostatitis with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.

Read the detailed description

A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

03

Conditions studied

  • Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Browse trials for

Keywords

  • prostatitis, chronic pelvic pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, at least 18 years of age
  • Has a total NIH-CPSI total score of 15
  • Has a NIH-CPSI pain score of 8
  • Has had pain in the pelvic region for at least 3 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Has previously participated in a Watson study with silodosin
  • Has previously received α-blocked therapy for chronic prostatitis/chronic pelvic pain syndrome or is currently receiving α-blocked therapy for any condition
  • Has experience ≥2 urinary tract infections within the previous 12 months
  • Has any medical condition that in the opinion of the investigator precludes safe participation in the study
  • Has any medical condition that could confound the efficacy evaluation
  • Is receiving ketoconazole, or other known potent inhibitors of cytochrome P450 3A4 or any medication in the opinion of the investigator that precludes safe participation in the study
  • Is receiving any medication that in the opinion of the investigator that could confound the efficacy evaluation
  • Has participated in a study involving the administration of an agent within the past 30 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Silodosin 4 mg

    4 mg daily

    Drug: Silodosin 4 mg

  • Experimental
    Silodosin 8 mg

    Silodosin 8 mg daily

    Drug: Silodosin 8 mg

  • Placebo comparator
    Placebo

    1 placebo capsule daily

    Drug: Placebo

Interventions

  • Silodosin 8 mg daily

    Also known as: Rapaflo

  • DrugPlacebo

    Placebo

    Also known as: Placebo control.

  • Silodosin 4 mg daily

    Also known as: Rapaflo

06

What researchers measure

Primary outcomes

  1. National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.

    Change from baseline In NIH-CPSI at Week 12. Three separate domain scores are calculated as pain, urinary symptoms, and quality of life impact. NIH-CPSI total score uses a 0 to 43 scale; 0 best, 43 worse symptoms.

    Time frame: 12 weeks

07

Results

Posted Feb 24, 2012

Participant flow

Participant flow — Overall Study
MilestoneSilodosin 4 mgSilodosin 8 mgPlacebo
Started524554
Completed433141
Not completed91413
Withdrew: Adverse event463
Withdrew: Protocol violation111
Withdrew: Lack of efficacy002
Withdrew: Withdrawal by subject242
Withdrew: Lost to follow-up235

Outcome measures

PrimaryNational Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.

Change from baseline In NIH-CPSI at Week 12. Three separate domain scores are calculated as pain, urinary symptoms, and quality of life impact. NIH-CPSI total score uses a 0 to 43 scale; 0 best, 43 worse symptoms.

Time frame:
12 weeks
Reported as:
Mean · Units on a 0 to 43 scale
National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.
Units on a 0 to 43 scaleSilodosin 4 mgSilodosin 8 mgPlacebo
Baseline NIH-CPSI Total Score26.0 ± 6.2926.8 ± 5.9427.9 ± 6.21
Chage from Baseline in NIH-CPSI at Week 12-12.1 ± 9.32-10.2 ± 8.84-8.5 ± 7.23

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Silodosin 4 mg—2/52 (3.8%)22/52 (42.3%)
Silodosin 8 mg—0/45 (0%)25/45 (55.6%)
Placebo—0/54 (0%)12/54 (22.2%)
Most frequent serious events
Most frequent serious events
EventSilodosin 4 mgSilodosin 8 mgPlacebo
UrosepsisInfections and infestations1/520/450/54
SyncopeNervous system disorders1/520/450/54
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSilodosin 4 mgSilodosin 8 mgPlacebo
Retrograde EjaculationReproductive system and breast disorders14/5218/451/54
DizzinessNervous system disorders1/525/454/54
Nasal CongestionRespiratory, thoracic and mediastinal disorders2/523/450/54
SinusitisInfections and infestations3/522/450/54
RashSkin and subcutaneous tissue disorders3/520/450/54
NauseaGastrointestinal disorders0/520/453/54
HeadacheNervous system disorders1/522/452/54
Libido DecreasedReproductive system and breast disorders1/522/451/54
DiarrhoeaGastrointestinal disorders2/520/450/54
Neurogenic BladderRenal and urinary disorders2/520/451/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Silodosin 4 mgSilodosin 8 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years444151136
>=65 years84315
Age Continuous
Age Continuous(years)Silodosin 4 mgSilodosin 8 mgPlaceboTotal
Mean49.2 ± 13.3446.7 ± 15.5749.0 ± 11.6248.4 ± 13.43
Sex: Female, Male
Sex: Female, Male(Participants)Silodosin 4 mgSilodosin 8 mgPlaceboTotal
Female0000
Male524554151
Region of Enrollment
Region of Enrollment(participants)Silodosin 4 mgSilodosin 8 mgPlaceboTotal
United States524554151
08

Study locations

22 sites
  • Watson Investigational Site
    San Diego, California, United States
  • Watson Investigational Site
    Denver, Colorado, United States
  • Watson Investigational Site
    Columbus, Georgia, United States
  • Watson Investigational Site
    Roswell, Georgia, United States
  • Watson Investigational Site
    Jeffersonville, Indiana, United States
  • Watson Investigational Site
    West Des Moines, Iowa, United States
  • Watson Investigational Site
    Baltimore, Maryland, United States
  • Watson Investigational Site
    Boston, Massachusetts, United States
  • Watson Investigational Site
    Watertown, Massachusetts, United States
  • Watson Investigational Site
    Omaha, Nebraska, United States
  • Watson Investigational Site
    Voorhees, New Jersey, United States
  • Watson Investigational Site
    Albuquerque, New Mexico, United States
  • Watson Investigational Site
    Garden City, New York, United States
  • Watson Investigational Site
    Kingston, New York, United States
  • Watson Investigational Site
    New York, New York, United States
  • Watson Investigational Site
    Poughkeepsie, New York, United States
  • Watson Investigational Site
    Columbus, Ohio, United States
  • Watson Investigational Site
    Bethany, Oklahoma, United States
  • Watson Investigational Site
    Edmond, Oklahoma, United States
  • Watson Investigational Site
    State College, Pennsylvania, United States
  • Watson Investigational Site
    Mountlake Terrace, Washington, United States
  • Watson Investigational Site
    Spokane, Washington, United States
09

References and documents

Publications

  • Nickel JC, O'Leary MP, Lepor H, Caramelli KE, Thomas H, Hill LA, Hoel GE. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol. 2011 Jul;186(1):125-31. doi: 10.1016/j.juro.2011.03.028. Epub 2011 May 14. PubMed 21571345 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2008
First posted
Aug 25, 2008
Start
Sep 2008
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Feb 24, 2012
Last update
Feb 24, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00740779
Responsible party
Sponsor
First posted
Aug 25, 2008
Start date
Sep 2008
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Feb 24, 2012
Last update
Feb 24, 2012

Study contacts

Kim Caramelli, MS
study director · Watson Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion